KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Operating Income (2016 - 2025)

Emergent BioSolutions (EBS) has 15 years of Operating Income data on record, last reported at -$27.9 million in Q4 2025.

  • For Q4 2025, Operating Income fell 193.68% year-over-year to -$27.9 million; the TTM value through Dec 2025 reached $100.1 million, up 192.09%, while the annual FY2025 figure was $100.1 million, 192.09% up from the prior year.
  • Operating Income reached -$27.9 million in Q4 2025 per EBS's latest filing, down from $76.5 million in the prior quarter.
  • Across five years, Operating Income topped out at $266.2 million in Q4 2021 and bottomed at -$292.9 million in Q2 2023.
  • Average Operating Income over 5 years is -$29.2 million, with a median of -$18.7 million recorded in 2024.
  • Peak YoY movement for Operating Income: soared 894.83% in 2021, then plummeted 2406.25% in 2023.
  • A 5-year view of Operating Income shows it stood at $266.2 million in 2021, then tumbled by 123.44% to -$62.4 million in 2022, then grew by 29.81% to -$43.8 million in 2023, then soared by 78.31% to -$9.5 million in 2024, then plummeted by 193.68% to -$27.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$27.9 million in Q4 2025, $76.5 million in Q3 2025, and $1.6 million in Q2 2025.